Respiratory and Systemic Infection Laboratory, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
Department of Biomedical Sciences, School of Life Sciences, University of Westminster, London W1W 6UW, UK.
J Med Microbiol. 2012 Dec;61(Pt 12):1662-1668. doi: 10.1099/jmm.0.049585-0. Epub 2012 Aug 23.
Molecular typing of Bordetella pertussis is routinely performed on bacterial isolates, but not on DNA extracted from nasopharyngeal aspirates or pernasal swabs submitted for diagnostic real-time PCR (qPCR). We investigated whether these DNA extracts were suitable for multilocus variable-number tandem repeat analysis (MLVA) and DNA sequence-based typing. We analysed all the available qPCR-positive samples received by our laboratory from patients <1 year of age between January 2008 and August 2010. Eighty-one per cent (106/131) of these generated a complete MLVA profile. This rose to 92 % (105/114) if only samples positive for both of the two targets used for the B. pertussis PCR (insertion element IS481 and pertussis toxin promoter ptxP) were analysed. Sequence-based typing of the pertactin, pertussis toxin S1 subunit and pertussis promoter regions (prn, ptxA and ptxP) was attempted on 89 of the DNA extracts that had generated a full MLVA profile. Eighty-three (93 %) of these produced complete sequences for all three targets. Comparison of molecular typing data from the 89 extracts with those from 111 contemporary bacterial isolates showed that the two sources yielded the same picture of the B. pertussis population [dominated by the MLVA-27 prn(2) ptxA(1) ptxP(3) clonal type]. There was no significant difference in MLVA type distribution or diversity between the two sample sets. This suggests that clinical extracts can be used in place of, or to complement, bacterial cultures for typing purposes (at least, in this age group). With small modifications to methodology, generating MLVA and sequence-based typing data from qPCR-positive clinical DNA extracts is likely to generate a complete dataset in the majority of samples from the <1 year age group. Its success with samples from older subjects remains to be seen. However, our data suggest that it is suitable for inclusion in molecular epidemiological studies of the B. pertussis population or as a tool in outbreak investigations.
对细菌分离株进行常规的百日咳博德特氏菌分子分型,但不进行从用于诊断实时 PCR(qPCR)的鼻咽抽吸物或经鼻拭子提取的 DNA 进行。我们研究了这些 DNA 提取物是否适合多位点可变数串联重复分析(MLVA)和基于 DNA 序列的分型。我们分析了 2008 年 1 月至 2010 年 8 月期间我们实验室收到的所有来自<1 岁患者的 qPCR 阳性样本。这些样本中有 81%(106/131)生成了完整的 MLVA 图谱。如果仅分析针对百日咳博德特氏菌 PCR(插入元件 IS481 和百日咳毒素启动子 ptxP)使用的两个靶标均为阳性的样本,则这一比例上升至 92%(105/114)。对 89 个生成完整 MLVA 图谱的 DNA 提取物进行了 pertactin、pertussis 毒素 S1 亚单位和 pertussis 启动子区域(prn、ptxA 和 ptxP)的基于序列的分型。这些提取物中有 83%(83/100)的提取物能够对所有三个靶标进行完整测序。对 89 个提取物的分子分型数据与 111 个当代细菌分离株的分子分型数据进行比较表明,这两个来源产生的百日咳博德特氏菌种群的图片相同[以 MLVA-27 prn(2) ptxA(1) ptxP(3)克隆型为主]。两个样本集之间的 MLVA 型分布或多样性没有显著差异。这表明,临床提取物可用于替代或补充细菌培养进行分型目的(至少在这个年龄组是这样)。通过对方法进行小的修改,从 qPCR 阳性临床 DNA 提取物生成 MLVA 和基于序列的分型数据,很可能会在<1 岁年龄组的大多数样本中生成完整的数据集。它在年龄较大的患者样本中的成功尚待观察。然而,我们的数据表明,它适合用于百日咳博德特氏菌种群的分子流行病学研究,或作为暴发调查的工具。